Mesenchymal Cells in Colon Cancer

Gastroenterology

Volumn 152, Issue 5, 2017, Pages 964-979

  Koliaraki, Vasiliki ^a   Pallangyo, Charles K ^b   Greten, Florian R ^c,d   Kollias, George ^a,e  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

CAF; Colon Cancer; IBD; Mesenchyme

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2; PROSTAGLANDIN E2; TUMOR MARKER;

ADAPTIVE IMMUNITY; ANGIOGENESIS; CANCER ASSOCIATED FIBROBLAST; CANCER CELL; CANCER PROGNOSIS; CELL FUNCTION; CELL SPECIFICITY; COLON CANCER; COLON CARCINOGENESIS; EPITHELIUM; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; INFLAMMATION; INNATE IMMUNITY; INTESTINE; INTESTINE CANCER; INTESTINE CELL; INTESTINE FUNCTION; INTRACELLULAR SIGNALING; MESENCHYME CELL; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; STEM CELL NICHE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLITIS; COLON TUMOR; CYTOLOGY; FIBROBLAST; MESENCHYMAL STROMA CELL; MYOFIBROBLAST; PERICYTE; SMOOTH MUSCLE CELL;

CANCER-ASSOCIATED FIBROBLASTS; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; COLITIS; COLONIC NEOPLASMS; EXTRACELLULAR MATRIX; FIBROBLASTS; HUMANS; INFLAMMATION; INTESTINES; MESENCHYMAL STROMAL CELLS; MYOCYTES, SMOOTH MUSCLE; MYOFIBROBLASTS; NEOVASCULARIZATION, PATHOLOGIC; PERICYTES; TUMOR MICROENVIRONMENT;

EID: 85016185050     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2016.11.049     Document Type: Review

References (168)

1. 1 Fearon, E.R., Vogelstein, B., A genetic model for colorectal tumorigenesis. Cell 61 (1990), 759–767.
2. 2 Wei, E.K., Giovannucci, E., Wu, K., et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer 108 (2004), 433–442.
3. 3 Terzic, J., Grivennikov, S., Karin, E., et al. Inflammation and colon cancer. Gastroenterology 138 (2010), 2101–2114.e5.
4. 4 Grivennikov, S.I., Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol 35 (2013), 229–244.
5. 5 Yaeger, R., Shah, M.A., Miller, V.A., et al. Genomic alterations observed in colitis-associated cancers are distinct from those found in sporadic colorectal cancers and vary by type of inflammatory bowel disease. Gastroenterology 151 (2016), 278–287.e6.
6. 6 Kalluri, R., Zeisberg, M., Fibroblasts in cancer. Nat Rev Cancer 6 (2006), 392–401.
7. 7 Sugimoto, H., Mundel, T.M., Kieran, M.W., et al. Identification of fibroblast heterogeneity in the tumor microenvironment. Cancer Biol Ther 5 (2006), 1640–1646.
8. 8 Rasanen, K., Vaheri, A., Activation of fibroblasts in cancer stroma. Exp Cell Res 316 (2010), 2713–2722.
9. 9 Kalluri, R., Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 3 (2003), 422–433.
10. 10 Allen, M., Louise Jones, J., Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol 223 (2011), 162–176.
11. 11 Mantovani, A., Allavena, P., Sica, A., et al. Cancer-related inflammation. Nature 454 (2008), 436–444.
12. 12 Quante, M., Varga, J., Wang, T.C., et al. The gastrointestinal tumor microenvironment. Gastroenterology 145 (2013), 63–78.
13. 13 Murdoch, C., Muthana, M., Coffelt, S.B., et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 8 (2008), 618–631.
14. 14 Butler, J.M., Kobayashi, H., Rafii, S., Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat Rev Cancer 10 (2010), 138–146.
15. 15 Hanahan, D., Coussens, L.M., Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21 (2012), 309–322.
16. 16 Powell, D.W., Pinchuk, I.V., Saada, J.I., et al. Mesenchymal cells of the intestinal lamina propria. Annu Rev Physiol 73 (2011), 213–237.
17. 17 Mifflin, R.C., Pinchuk, I.V., Saada, J.I., et al. Intestinal myofibroblasts: targets for stem cell therapy. Am J Physiol Gastrointest Liver Physiol 300 (2011), G684–G696.
18. 18 Peng, H., Herzog, E.L., Fibrocytes: emerging effector cells in chronic inflammation. Curr Opin Pharmacol 12 (2012), 491–496.
19. 19 Sanders, K.M., Ward, S.M., Koh, S.D., Interstitial cells: regulators of smooth muscle function. Physiol Rev 94 (2014), 859–907.
20. 20 Prados, A., Kollias, G., Koliaraki, V., CollagenVI-Cre mice: a new tool to target stromal cells in secondary lymphoid organs. Sci Rep, 6, 2016, 33027.
21. 21 Hsia, L.T., Ashley, N., Ouaret, D., et al. Myofibroblasts are distinguished from activated skin fibroblasts by the expression of AOC3 and other associated markers. Proc Natl Acad Sci U S A 113 (2016), E2162–E2171.
22. 22 McLin, V.A., Henning, S.J., Jamrich, M., The role of the visceral mesoderm in the development of the gastrointestinal tract. Gastroenterology 136 (2009), 2074–2091.
23. 23 Wilm, B., Ipenberg, A., Hastie, N.D., et al. The serosal mesothelium is a major source of smooth muscle cells of the gut vasculature. Development 132 (2005), 5317–5328.
24. 24 Rinkevich, Y., Mori, T., Sahoo, D., et al. Identification and prospective isolation of a mesothelial precursor lineage giving rise to smooth muscle cells and fibroblasts for mammalian internal organs, and their vasculature. Nat Cell Biol 14 (2012), 1251–1260.
25. 25 Brown, S.L., Riehl, T.E., Walker, M.R., et al. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J Clin Invest 117 (2007), 258–269.
26. 26 Walker, M.R., Brown, S.L., Riehl, T.E., et al. Growth factor regulation of prostaglandin-endoperoxide synthase 2 (Ptgs2) expression in colonic mesenchymal stem cells. J Biol Chem 285 (2010), 5026–5039.
27. 27 Manieri, N.A., Drylewicz, M.R., Miyoshi, H., et al. Igf2bp1 is required for full induction of Ptgs2 mRNA in colonic mesenchymal stem cells in mice. Gastroenterology 143 (2012), 110–121.e10.
28. 28 Armulik, A., Genove, G., Betsholtz, C., Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 21 (2011), 193–215.
29. 29 Tommelein, J., Verset, L., Boterberg, T., et al. Cancer-associated fibroblasts connect metastasis-promoting communication in colorectal cancer. Front Oncol, 5, 2015, 63.
30. 30 Servais, C., Erez, N., From sentinel cells to inflammatory culprits: cancer-associated fibroblasts in tumour-related inflammation. J Pathol 229 (2013), 198–207.
31. 31 De, L.K.T., Whiting, C.V., Bland, P.W., Proinflammatory cytokine synthesis by mucosal fibroblasts from mouse colitis is enhanced by interferon-gamma-mediated up-regulation of CD40 signalling. Clin Exp Immunol 147 (2007), 313–323.
32. 32 Buckley, C.D., Pilling, D., Lord, J.M., et al. Fibroblasts regulate the switch from acute resolving to chronic persistent inflammation. Trends Immunol 22 (2001), 199–204.
33. 33 Kalluri, R., The biology and function of fibroblasts in cancer. Nat Rev Cancer 16 (2016), 582–598.
34. 34 Hinz, B., Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 127 (2007), 526–537.
35. 35 Dvorak, H.F., Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 315 (1986), 1650–1659.
36. 36 Bissell, M.J., Hines, W.C., Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 17 (2011), 320–329.
37. 37 Augsten, M., Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol, 4, 2014, 62.
38. 38 Calon, A., Lonardo, E., Berenguer-Llergo, A., et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 47 (2015), 320–329.
39. 39 Isella, C., Terrasi, A., Bellomo, S.E., et al. Stromal contribution to the colorectal cancer transcriptome. Nat Genet 47 (2015), 312–319.
40. 40 Tsujino, T., Seshimo, I., Yamamoto, H., et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res 13 (2007), 2082–2090.
41. 41 Ohlund, D., Elyada, E., Tuveson, D., Fibroblast heterogeneity in the cancer wound. J Exp Med 211 (2014), 1503–1523.
42. 42 Cortez, E., Roswall, P., Pietras, K., Functional subsets of mesenchymal cell types in the tumor microenvironment. Semin Cancer Biol 25 (2014), 3–9.
43. 43 Brenmoehl, J., Miller, S.N., Hofmann, C., et al. Transforming growth factor-beta 1 induces intestinal myofibroblast differentiation and modulates their migration. World J Gastroenterol 15 (2009), 1431–1442.
44. 44 Hawinkels, L.J., Paauwe, M., Verspaget, H.W., et al. Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts. Oncogene 33 (2014), 97–107.
45. 45 Calon, A., Espinet, E., Palomo-Ponce, S., et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22 (2012), 571–584.
46. 46 Grillo, A.R., Scarpa, M., D'Inca, R., et al. TAK1 is a key modulator of the profibrogenic phenotype of human ileal myofibroblasts in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 309 (2015), G443–G454.
47. 47 Theiss, A.L., Simmons, J.G., Jobin, C., et al. Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 280 (2005), 36099–36109.
48. 48 Flier, S.N., Tanjore, H., Kokkotou, E.G., et al. Identification of epithelial to mesenchymal transition as a novel source of fibroblasts in intestinal fibrosis. J Biol Chem 285 (2010), 20202–20212.
49. 49 Polyak, K., Weinberg, R.A., Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 9 (2009), 265–273.
50. 50 Brittan, M., Hunt, T., Jeffery, R., et al. Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut 50 (2002), 752–757.
51. 51 Kidd, S., Spaeth, E., Watson, K., et al. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One, 7, 2012, e30563.
52. 52 Quante, M., Tu, S.P., Tomita, H., et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19 (2011), 257–272.
53. 53 Shibata, W., Ariyama, H., Westphalen, C.B., et al. Stromal cell-derived factor-1 overexpression induces gastric dysplasia through expansion of stromal myofibroblasts and epithelial progenitors. Gut 62 (2013), 192–200.
54. 54 Worthley, D.L., Ruszkiewicz, A., Davies, R., et al. Human gastrointestinal neoplasia-associated myofibroblasts can develop from bone marrow-derived cells following allogeneic stem cell transplantation. Stem Cells 27 (2009), 1463–1468.
55. 55 Worthley, D.L., Giraud, A.S., Wang, T.C., Stromal fibroblasts in digestive cancer. Cancer Microenviron 3 (2010), 117–125.
56. 56 Calon, A., Tauriello, D.V., Batlle, E., TGF-beta in CAF-mediated tumor growth and metastasis. Semin Cancer Biol 25 (2014), 15–22.
57. 57 Bhowmick, N.A., Chytil, A., Plieth, D., et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303 (2004), 848–851.
58. 58 Okuno, T., Andoh, A., Bamba, S., et al. Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol 37 (2002), 317–324.
59. 59 Erez, N., Truitt, M., Olson, P., et al. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting inflammation in an NF-kappaB-dependent manner. Cancer Cell 17 (2010), 135–147.
60. 60 Andoh, A., Bamba, S., Brittan, M., et al. Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther 114 (2007), 94–106.
61. 61 Yagi, Y., Andoh, A., Inatomi, O., et al. Inflammatory responses induced by interleukin-17 family members in human colonic subepithelial myofibroblasts. J Gastroenterol 42 (2007), 746–753.
62. 62 Yagi, Y., Andoh, A., Nishida, A., et al. Interleukin-31 stimulates production of inflammatory mediators from human colonic subepithelial myofibroblasts. Int J Mol Med 19 (2007), 941–946.
63. 63 Takahashi, K., Imaeda, H., Fujimoto, T., et al. Regulation of eotaxin-3/CC chemokine ligand 26 expression by T helper type 2 cytokines in human colonic myofibroblasts. Clin Exp Immunol 173 (2013), 323–331.
64. 64 Pribluda, A., Elyada, E., Wiener, Z., et al. A senescence-inflammatory switch from cancer-inhibitory to cancer-promoting mechanism. Cancer Cell 24 (2013), 242–256.
65. 65 Aran, D., Lasry, A., Zinger, A., et al. Widespread parainflammation in human cancer. Genome Biol, 17, 2016, 145.
66. 66 Campisi, J., Aging, cellular senescence, and cancer. Annu Rev Physiol 75 (2013), 685–705.
67. 67 Neufert, C., Becker, C., Neurath, M.F., An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc 2 (2007), 1998–2004.
68. 68 Moser, A.R., Pitot, H.C., Dove, W.F., A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247 (1990), 322–324.
69. 69 Glaire, M.A., El-Omar, E.M., Wang, T.C., et al. The mesenchyme in malignancy: a partner in the initiation, progression and dissemination of cancer. Pharmacol Ther 136 (2012), 131–141.
70. 70 Otte, J.M., Rosenberg, I.M., Podolsky, D.K., Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124 (2003), 1866–1878.
71. 71 Walton, K.L., Holt, L., Sartor, R.B., Lipopolysaccharide activates innate immune responses in murine intestinal myofibroblasts through multiple signaling pathways. Am J Physiol Gastrointest Liver Physiol 296 (2009), G601–G611.
72. 72 Torres, S., Bartolome, R.A., Mendes, M., et al. Proteome profiling of cancer-associated fibroblasts identifies novel proinflammatory signatures and prognostic markers for colorectal cancer. Clin Cancer Res 19 (2013), 6006–6019.
73. 73 Herrera, M., Herrera, A., Dominguez, G., et al. Cancer-associated fibroblast and M2 macrophage markers together predict outcome in colorectal cancer patients. Cancer Sci 104 (2013), 437–444.
74. 74 Koliaraki, V., Pasparakis, M., Kollias, G., IKKbeta in intestinal mesenchymal cells promotes initiation of colitis-associated cancer. J Exp Med 212 (2015), 2235–2251.
75. 75 Bollrath, J., Phesse, T.J., von Burstin, V.A., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15 (2009), 91–102.
76. 76 Grivennikov, S., Karin, E., Terzic, J., et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15 (2009), 103–113.
77. 77 Becker, C., Fantini, M.C., Schramm, C., et al. TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21 (2004), 491–501.
78. 78 Shaker, A., Swietlicki, E.A., Wang, L., et al. Epimorphin deletion protects mice from inflammation-induced colon carcinogenesis and alters stem cell niche myofibroblast secretion. J Clin Invest 120 (2010), 2081–2093.
79. 79 Shaker, A., Gargus, M., Fink, J., et al. Epimorphin(-/-) mice are protected, in part, from acute colitis via decreased interleukin 6 signaling. Transl Res 164 (2014), 70–83.
80. 80 Pallangyo, C.K., Ziegler, P.K., Greten, F.R., IKKbeta acts as a tumor suppressor in cancer-associated fibroblasts during intestinal tumorigenesis. J Exp Med 212 (2015), 2253–2266.
81. 81 Wagner, E.F., Cancer: fibroblasts for all seasons. Nature 530 (2016), 42–43.
82. 82 Saada, J.I., Pinchuk, I.V., Barrera, C.A., et al. Subepithelial myofibroblasts are novel nonprofessional APCs in the human colonic mucosa. J Immunol 177 (2006), 5968–5979.
83. 83 Roberts, A.I., Nadler, S.C., Ebert, E.C., Mesenchymal cells stimulate human intestinal intraepithelial lymphocytes. Gastroenterology 113 (1997), 144–150.
84. 84 Pinchuk, I.V., Saada, J.I., Beswick, E.J., et al. PD-1 ligand expression by human colonic myofibroblasts/fibroblasts regulates CD4+ T-cell activity. Gastroenterology 135 (2008), 1228–1237 1237 e1–2.
85. 85 Beswick, E.J., Johnson, J.R., Saada, J.I., et al. TLR4 activation enhances the PD-L1-mediated tolerogenic capacity of colonic CD90+ stromal cells. J Immunol 193 (2014), 2218–2229.
86. 86 Pinchuk, I.V., Beswick, E.J., Saada, J.I., et al. Human colonic myofibroblasts promote expansion of CD4+ CD25high Foxp3+ regulatory T cells. Gastroenterology 140 (2011), 2019–2030.
87. 87 Musso, A., Condon, T.P., West, G.A., et al. Regulation of ICAM-1-mediated fibroblast-T cell reciprocal interaction: implications for modulation of gut inflammation. Gastroenterology 117 (1999), 546–556.
88. 88 Wang, D., Dubois, R.N., The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene 29 (2010), 781–788.
89. 89 Greenhough, A., Smartt, H.J., Moore, A.E., et al. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30 (2009), 377–386.
90. 90 Eberhart, C.E., Coffey, R.J., Radhika, A., et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107 (1994), 1183–1188.
91. 91 Adegboyega, P.A., Ololade, O., Saada, J., et al. Subepithelial myofibroblasts express cyclooxygenase-2 in colorectal tubular adenomas. Clin Cancer Res 10 (2004), 5870–5879.
92. 92 Elder, D.J., Paraskeva, C., COX-2 inhibitors for colorectal cancer. Nat Med 4 (1998), 392–393.
93. 93 Sostres, C., Gargallo, C.J., Lanas, A., Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage. Arthritis Res Ther, 15(suppl 3), 2013, S3.
94. 94 Shattuck-Brandt, R.L., Varilek, G.W., Radhika, A., et al. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterology 118 (2000), 337–345.
95. 95 Oshima, M., Dinchuk, J.E., Kargman, S.L., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996), 803–809.
96. 96 Williams, C.S., Luongo, C., Radhika, A., et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111 (1996), 1134–1140.
97. 97 Cherukuri, D.P., Ishikawa, T.O., Chun, P., et al. Targeted Cox2 gene deletion in intestinal epithelial cells decreases tumorigenesis in female, but not male, ApcMin/+ mice. Mol Oncol 8 (2014), 169–177.
98. 98 Chulada, P.C., Thompson, M.B., Mahler, J.F., et al. Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 60 (2000), 4705–4708.
99. 99 Oshima, M., Murai, N., Kargman, S., et al. Chemoprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 61 (2001), 1733–1740.
100. 100 Wang, D., Fu, L., Sun, H., et al. Prostaglandin E2 promotes colorectal cancer stem cell expansion and metastasis in mice. Gastroenterology 149 (2015), 1884–1895 e4.
101. 101 Tessner, T.G., Cohn, S.M., Schloemann, S., et al. Prostaglandins prevent decreased epithelial cell proliferation associated with dextran sodium sulfate injury in mice. Gastroenterology 115 (1998), 874–882.
102. 102 Tessner, T.G., Muhale, F., Riehl, T.E., et al. Prostaglandin E2 reduces radiation-induced epithelial apoptosis through a mechanism involving AKT activation and bax translocation. J Clin Invest 114 (2004), 1676–1685.
103. 103 Rodriguez Perez, C.E., Nie, W., Sinnett-Smith, J., et al. TNF-alpha potentiates lysophosphatidic acid-induced COX-2 expression via PKD in human colonic myofibroblasts. Am J Physiol Gastrointest Liver Physiol 300 (2011), G637–G646.
104. 104 Roulis, M., Nikolaou, C., Kotsaki, E., et al. Intestinal myofibroblast-specific Tpl2-Cox-2-PGE2 pathway links innate sensing to epithelial homeostasis. Proc Natl Acad Sci U S A 111 (2014), E4658–E4667.
105. 105 Nakamura, T., Sakai, K., Matsumoto, K., Hepatocyte growth factor twenty years on: Much more than a growth factor. J Gastroenterol Hepatol 26:suppl 1 (2011), 188–202.
106. 106 Bhowmick, N.A., Neilson, E.G., Moses, H.L., Stromal fibroblasts in cancer initiation and progression. Nature 432 (2004), 332–337.
107. 107 Hamilton, K.E., Chatterji, P., Lundsmith, E.T., et al. Loss of stromal IMP1 promotes a tumorigenic microenvironment in the colon. Mol Cancer Res 13 (2015), 1478–1486.
108. 108 Koliaraki, V., Roulis, M., Kollias, G., Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis. J Clin Invest 122 (2012), 4231–4242.
109. 109 Swietlicki, E.A., Bala, S., Lu, J., et al. Epimorphin deletion inhibits polyposis in the Apcmin/+ mouse model of colon carcinogenesis via decreased myofibroblast HGF secretion. Am J Physiol Gastrointest Liver Physiol 305 (2013), G564–G572.
110. 110 Brandl, K., Sun, L., Neppl, C., et al. MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands. Proc Natl Acad Sci U S A 107 (2010), 19967–19972.
111. 111 Neufert, C., Becker, C., Tureci, O., et al. Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest 123 (2013), 1428–1443.
112. 112 Chivukula, R.R., Shi, G., Acharya, A., et al. An essential mesenchymal function for miR-143/145 in intestinal epithelial regeneration. Cell 157 (2014), 1104–11016.
113. 113 Putoczki, T.L., Thiem, S., Loving, A., et al. Interleukin-11 is the dominant IL-6 family cytokine during gastrointestinal tumorigenesis and can be targeted therapeutically. Cancer Cell 24 (2013), 257–271.
114. 114 Mahapatro, M., Foersch, S., Hefele, M., et al. Programming of intestinal epithelial differentiation by IL-33 derived from pericryptal fibroblasts in response to systemic infection. Cell Rep 15 (2016), 1743–1756.
115. 115 Maywald, R.L., Doerner, S.K., Pastorelli, L., et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci U S A 112 (2015), E2487–E2496.
116. 116 Hardwick, J.C., Kodach, L.L., Offerhaus, G.J., et al. Bone morphogenetic protein signalling in colorectal cancer. Nat Rev Cancer 8 (2008), 806–812.
117. 117 van den Brink, G.R., Rubin, D.C., Foxf2: a mesenchymal regulator of intestinal adenoma development. Gastroenterology 144 (2013), 873–876.
118. 118 Ormestad, M., Astorga, J., Landgren, H., et al. Foxf1 and Foxf2 control murine gut development by limiting mesenchymal Wnt signaling and promoting extracellular matrix production. Development 133 (2006), 833–843.
119. 119 Nik, A.M., Reyahi, A., Ponten, F., et al. Foxf2 in intestinal fibroblasts reduces numbers of Lgr5(+) stem cells and adenoma formation by inhibiting Wnt signaling. Gastroenterology 144 (2013), 1001–1011.
120. 120 Vermeulen, L., De Sousa, E.M.F., van der Heijden, M., et al. Wnt activity defines colon cancer stem cells and is regulated by the microenvironment. Nat Cell Biol 12 (2010), 468–476.
121. 121 Theunissen, J.W., de Sauvage, F.J., Paracrine Hedgehog signaling in cancer. Cancer Res 69 (2009), 6007–6010.
122. 122 Yauch, R.L., Gould, S.E., Scales, S.J., et al. A paracrine requirement for hedgehog signalling in cancer. Nature 455 (2008), 406–410.
123. 123 Berlin, J., Bendell, J.C., Hart, L.L., et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 19 (2013), 258–267.
124. 124 Gerling, M., Buller, N.V., Kirn, L.M., et al. Stromal Hedgehog signalling is downregulated in colon cancer and its restoration restrains tumour growth. Nat Commun, 7, 2016, 12321.
125. 125 Micke, P., Ostman, A., Exploring the tumour environment: cancer-associated fibroblasts as targets in cancer therapy. Expert Opin Ther Targets 9 (2005), 1217–1233.
126. 126 Peddareddigari, V.G., Wang, D., Dubois, R.N., The tumor microenvironment in colorectal carcinogenesis. Cancer Microenviron 3 (2010), 149–166.
127. 127 Fukumura, D., Xavier, R., Sugiura, T., et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 94 (1998), 715–725.
128. 128 O'Connell, J.T., Sugimoto, H., Cooke, V.G., et al. VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A 108 (2011), 16002–16007.
129. 129 Manieri, N.A., Mack, M.R., Himmelrich, M.D., et al. Mucosally transplanted mesenchymal stem cells stimulate intestinal healing by promoting angiogenesis. J Clin Invest 125 (2015), 3606–3618.
130. 130 Bonnans, C., Chou, J., Werb, Z., Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 15 (2014), 786–801.
131. 131 Catalano, V., Turdo, A., Di Franco, S., et al. Tumor and its microenvironment: a synergistic interplay. Semin Cancer Biol 23 (2013), 522–532.
132. 132 De Wever, O., Van Bockstal, M., Mareel, M., et al. Carcinoma-associated fibroblasts provide operational flexibility in metastasis. Semin Cancer Biol 25 (2014), 33–46.
133. 133 Bamba, S., Andoh, A., Yasui, H., et al. Matrix metalloproteinase-3 secretion from human colonic subepithelial myofibroblasts: role of interleukin-17. J Gastroenterol 38 (2003), 548–554.
134. 134 McKaig, B.C., McWilliams, D., Watson, S.A., et al. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162 (2003), 1355–1360.
135. 135 Levental, K.R., Yu, H., Kass, L., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906.
136. 136 Zheng, L., Riehl, T.E., Stenson, W.F., Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology 137 (2009), 2041–2051.
137. 137 Kobayashi, N., Miyoshi, S., Mikami, T., et al. Hyaluronan deficiency in tumor stroma impairs macrophage trafficking and tumor neovascularization. Cancer Res 70 (2010), 7073–7083.
138. 138 Kessenbrock, K., Plaks, V., Werb, Z., Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141 (2010), 52–67.
139. 139 Vellinga, T.T., den Uil, S., Rinkes, I.H., et al. Collagen-rich stroma in aggressive colon tumors induces mesenchymal gene expression and tumor cell invasion. Oncogene 35 (2016), 5263–5271.
140. 140 Henry, L.R., Lee, H.O., Lee, J.S., et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 13 (2007), 1736–1741.
141. 141 Yamanashi, T., Nakanishi, Y., Fujii, G., et al. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology 77 (2009), 53–62.
142. 142 Berdiel-Acer, M., Berenguer, A., Sanz-Pamplona, R., et al. A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer. Oncotarget 5 (2014), 6437–6452.
143. 143 De Sousa, E.M.F., Wang, X., Jansen, M., et al. Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions. Nat Med 19 (2013), 614–618.
144. 144 Sadanandam, A., Lyssiotis, C.A., Homicsko, K., et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med 19 (2013), 619–625.
145. 145 Kim, H., Verhaak, R.G., Transcriptional mimicry by tumor-associated stroma. Nat Genet 47 (2015), 307–309.
146. 146 Sanchez-Lopez, E., Flashner-Abramson, E., Shalapour, S., et al. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 35 (2016), 2634–2644.
147. 147 Khawar, I.A., Kim, J.H., Kuh, H.J., Improving drug delivery to solid tumors: priming the tumor microenvironment. J Control Release 201 (2015), 78–89.
148. 148 Gascard, P., Tlsty, T.D., Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev 30 (2016), 1002–1019.
149. 149 Santos, A.M., Jung, J., Aziz, N., et al. Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in mice. J Clin Invest 119 (2009), 3613–3625.
150. 150 Chan, A.T., Ogino, S., Fuchs, C.S., Aspirin use and survival after diagnosis of colorectal cancer. JAMA 302 (2009), 649–658.
151. 151 Waldner, M.J., Foersch, S., Neurath, M.F., Interleukin-6–a key regulator of colorectal cancer development. Int J Biol Sci 8 (2012), 1248–1253.
152. 152 Comoglio, P.M., Giordano, S., Trusolino, L., Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 7 (2008), 504–516.
153. 153 Straussman, R., Morikawa, T., Shee, K., et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487 (2012), 500–504.
154. 154 Dufour, A., Overall, C.M., Missing the target: matrix metalloproteinase antitargets in inflammation and cancer. Trends Pharmacol Sci 34 (2013), 233–242.
155. 155 Maruyama, T., Hatakeyama, S., Miwa, T., et al. Human smooth muscle alpha-actin promoter drives Cre recombinase expression in the cranial suture in addition to smooth muscle cell. Biosci Biotechnol Biochem 71 (2007), 1103–1106.
156. 156 Wu, Z., Yang, L., Cai, L., et al. Detection of epithelial to mesenchymal transition in airways of a bleomycin induced pulmonary fibrosis model derived from an alpha-smooth muscle actin-Cre transgenic mouse. Respir Res, 8, 2007, 1.
157. 157 Wendling, O., Bornert, J.M., Chambon, P., et al. Efficient temporally-controlled targeted mutagenesis in smooth muscle cells of the adult mouse. Genesis 47 (2009), 14–18.
158. 158 Zheng, B., Zhang, Z., Black, C.M., et al. Ligand-dependent genetic recombination in fibroblasts: a potentially powerful technique for investigating gene function in fibrosis. Am J Pathol 160 (2002), 1609–1617.
159. 159 Armaka, M., Apostolaki, M., Jacques, P., et al. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J Exp Med 205 (2008), 331–337.
160. 160 Sackett, S.D., Fulmer, J.T., Friedman, J.R., et al. Foxl1-Cre BAC transgenic mice: a new tool for gene ablation in the gastrointestinal mesenchyme. Genesis 45 (2007), 518–522.
161. 161 Aoki, R., Shoshkes-Carmel, M., Gao, N., et al. Foxl1-expressing mesenchymal cells constitute the intestinal stem cell niche. Cell Mol Gastroenterol Hepatol 2 (2016), 175–188.
162. 162 Osterreicher, C.H., Penz-Osterreicher, M., Grivennikov, S.I., et al. Fibroblast-specific protein 1 identifies an inflammatory subpopulation of macrophages in the liver. Proc Natl Acad Sci U S A 108 (2011), 308–313.
163. 163 Worthley, D.L., Churchill, M., Compton, J.T., et al. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell 160 (2015), 269–284.
164. 164 Xin, H.B., Deng, K.Y., Rishniw, M., et al. Smooth muscle expression of Cre recombinase and eGFP in transgenic mice. Physiol Genomics 10 (2002), 211–215.
165. 165 Wirth, A., Benyo, Z., Lukasova, M., et al. G12-G13-LARG-mediated signaling in vascular smooth muscle is required for salt-induced hypertension. Nat Med 14 (2008), 64–68.
166. 166 Maezawa, Y., Binnie, M., Li, C., et al. A new Cre driver mouse line, Tcf21/Pod1-Cre, targets metanephric mesenchyme. PLoS One, 7, 2012, e40547.
167. 167 Sosic, D., Richardson, J.A., Yu, K., et al. Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell 112 (2003), 169–180.
168. 168 Troeger, J.S., Mederacke, I., Gwak, G.Y., et al. Deactivation of hepatic stellate cells during liver fibrosis resolution in mice. Gastroenterology 143 (2012), 1073–1083 e22.